Dr. Lisa Landrum
Claim this profileIndiana University/Melvin and Bren Simon Cancer Center
Studies Ovarian Cancer
Studies Recurrence
13 reported clinical trials
28 drugs studied
Area of expertise
1Ovarian Cancer
BRCA1 positive
Stage II
Stage III
2Recurrence
Stage IV
Stage III
MLH1 positive
Affiliated Hospitals
Clinical Trials Lisa Landrum is currently running
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
Ipatasertib + Megestrol Acetate
for Endometrial Cancer
This trial is testing if combining two drugs, ipatasertib and megestrol acetate, is more effective than using megestrol acetate alone for treating women with endometrial cancer that has returned or spread. Ipatasertib blocks enzymes needed for cancer cell growth, while megestrol acetate reduces and blocks estrogen, which some cancer cells need to grow.
Recruiting1 award Phase 1 & 2
More about Lisa Landrum
Clinical Trial Related2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Lisa Landrum has experience with
- Bevacizumab
- Paclitaxel
- Carboplatin
- Selinexor
- Matching Placebo For Selinexor
- Mirvetuximab Soravtansine
Breakdown of trials Lisa Landrum has run
Ovarian Cancer
Recurrence
Endometrial Cancer
Ovarian Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lisa Landrum specialize in?
Lisa Landrum focuses on Ovarian Cancer and Recurrence. In particular, much of their work with Ovarian Cancer has involved BRCA1 positive patients, or patients who are Stage II.
Is Lisa Landrum currently recruiting for clinical trials?
Yes, Lisa Landrum is currently recruiting for 7 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Lisa Landrum has studied deeply?
Yes, Lisa Landrum has studied treatments such as Bevacizumab, Paclitaxel, Carboplatin.
What is the best way to schedule an appointment with Lisa Landrum?
Apply for one of the trials that Lisa Landrum is conducting.
What is the office address of Lisa Landrum?
The office of Lisa Landrum is located at: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University/Melvin and Bren Simon Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.